Repligen (RGEN)

• Market cap: $7.16B
• 1 day: -2.88%
• 5 days: -2.13%
• 1 month: -3.06%
• 3 months: -10.47%
• 6 months: -18.47%
• Year to date: -10.86%
• 1 year: 1.25%
• 5 years: 11.91%
• 10 years: 229.08%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Employees: 1,778

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

38% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 45

29% more repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 130

2% more funds holding

Funds holding: 429 [Q4 2024] → 438 (+9) [Q1 2025]

1.37% more ownership

Funds ownership: 100.37% [Q4 2024] → 101.74% (+1.37%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

10% less capital invested

Capital invested by funds: $8.09B [Q4 2024] → $7.31B (-$786M) [Q1 2025]

84% less call options, than puts

Call options by funds: $11M | Put options by funds: $68.6M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $150 18% upside
• Avg. target: $173 36% upside
• High target: $190 49% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	41% upside $180	Buy Reiterated	5 May 2025
RBC Capital Conor McNamara	48% upside $189	Outperform Maintained	30 Apr 2025
JP Morgan Rachel Vatnsdal	49% upside $190	Overweight Maintained	29 Apr 2025
Canaccord Genuity Kyle Mikson	18% upside $150	Hold Maintained	16 Apr 2025
Evercore ISI Group Daniel Markowitz	22% upside $155	In-Line Initiated	18 Mar 2025